Jiawei Zheng | Toxicology | Excellence in Research Award

Published on by Cognitive Scientist Awards

Mr. Jiawei Zheng | Toxicology | Excellence in Research Award 

Jinquan Satellite Launch Center Hospital | China

Jiawei Zheng is an attending doctor at the Jiuquan Satellite Launch Center Hospital whose work integrates clinical practice with specialized research in occupational toxicology, particularly focusing on hepatotoxicity mechanisms relevant to aerospace environments. Trained in medical sciences with a concentration in toxicology, he has built a career that blends laboratory investigation with applied aerospace-medicine service, serving as a principal investigator for internally supported projects aimed at understanding and mitigating toxin-induced organ injury. His research explores oxidative stress, apoptosis signaling, and metabolic intervention, with special emphasis on the pathways disrupted by exposure to aerospace-related chemicals. He has developed strong skills in experimental design, animal modeling, cellular and biochemical analysis, mechanistic interpretation, and scientific writing, demonstrated through his first-author contribution to a peer-reviewed article that reveals a novel mechanistic pathway underlying UDMH-induced liver injury. His professional experience also includes leading a hospital consultancy initiative focused on toxicological risk assessment. Although early in his publication journey, his work has already contributed meaningful insights to the field of hepatotoxicity research. With dedication to advancing occupational health protection for aerospace personnel, he continues to pursue research that supports scientific innovation, clinical safety, and the broader mission of improving health resilience in high-risk technological environments.

Profile: ORCID

Featured Publications

Zheng, J., Liu, W., Zhu, X., Ran, L., Lang, H., Yi, L., Mi, M., & Zhu, J. (2020). Pterostilbene enhances endurance capacity via promoting skeletal muscle adaptations to exercise training in rats. Molecules, 25(1), 186.

Huang, Y., Zhu, X., Chen, K., Lang, H., Zhang, Y., Hou, P., Ran, L., Zhou, M., Zheng, J., Yi, L., & Mi, M. (2019). Resveratrol prevents sarcopenic obesity by reversing mitochondrial dysfunction and oxidative stress via the PKA/LKB1/AMPK pathway. Aging (Albany NY), 11(8), 2217–2240.

 

Yue Dong | Neurodegeneration | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Yue Dong | Neurodegeneration | Best Researcher Award

Hebei Hospital of Xuanwu Hospital | China

Dr. Yue Dong is a research scientist specialising in Alzheimer’s disease, neuromodulation, and translational neuroscience, with work rooted in uncovering metabolic, molecular, and circuit-level mechanisms of cognitive vulnerability while advancing non-invasive brain-stimulation technologies. She holds a medical degree from Hebei Medical University and a doctoral degree in biomedical engineering from the University of California, Irvine, followed by postdoctoral training at leading American institutions, where she deepened her expertise in neurodegeneration, electrophysiology, multi-omics analysis, network imaging, and cellular–circuit physiology. Her professional experience spans neuroscience, biomedical engineering, and clinical translation, and she currently serves as a researcher at Hebei Hospital of Xuanwu Hospital, contributing to precision neuromodulation research. Her interests include Alzheimer’s pathology, brain aging, sleep–memory interactions, synaptic resilience, photobiomodulation, and AI-enabled wearable stimulation systems. She is skilled in multi-omics profiling, fluorescence lifetime imaging, fMRI and EEG analytics, metabolic modelling, and neuromodulation parameter optimisation. Her work has earned recognition through competitive national and provincial research grants, talent awards, and leadership roles in professional societies. Dr. Dong’s career reflects a commitment to advancing mechanistic discovery and real-world clinical innovation, with the overarching goal of transforming neuromodulation into accessible, scalable brain-health technology for future therapeutic applications.

Profile: Googlescholar

Featured Publications

Hashem Shahroosvand | Anticancer and Immunologist | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Dr. Hashem Shahroosvand | Anticancer and Immunologist | Best Researcher Award

University of Zanjan | Iran

Prof. Hashem Shahroosvand is an accomplished researcher in organic electronics, solar energy materials, and advanced photonic systems, recognised for influential contributions to dye-sensitized and perovskite solar cell technology as well as light-emitting electrochemical devices. He holds strong academic foundations through advanced training and qualifications in chemistry and materials science, complemented by progressive academic appointments at the University of Zanjan, where he has built an active research programme in molecular engineering and optoelectronic materials. His professional experience spans collaborative projects with leading international groups in photovoltaics and light-emitting devices, and his work has attracted sustained citations, reflecting significant impact across energy-related materials research. His research interests include molecular design of transition-metal complexes, development of hole-transport materials, photophysical property tuning, and the creation of highly efficient electroluminescent systems. He is skilled in synthetic chemistry, spectral and electrochemical analysis, device fabrication, and structure-property correlation studies. His achievements include recognition through strong publication records, invited collaborations, and contributions to high-impact review and research articles across premier journals in chemistry and materials science. Overall, he is a dedicated scientist whose work continues to advance renewable-energy materials and molecular optoelectronic technologies, positioning him as an influential contributor to the future of functional materials research.

Profile: Googlescholar

Featured Publications

David Blum | Neurodegeneration | Best Academic Researcher Award

Published on by Cognitive Scientist Awards

Dr. David Blum | Neurodegeneration | Best Academic Researcher Award

Inserm | France

Dr. David Blum is a leading physiologist and neuroscientist specialising in neurodegeneration, serving as a research director at Inserm within a prominent laboratory dedicated to Alzheimer’s disease and tauopathies. He completed his academic training in physiology and neuroscience, building a strong foundation that guides his work on the molecular and cellular mechanisms underlying neurodegenerative disorders. His professional experience includes extensive leadership in research programmes focused on Tau biology, metabolic regulation, neuroinflammation, and purinergic signalling, with particular emphasis on adenosine pathways. His research interests centre on understanding how Tau pathology disrupts memory, synaptic plasticity, and cognitive function, as well as exploring environmental, metabolic, and epigenomic contributors to disease progression. He possesses advanced research skills in experimental neuroscience, molecular physiology, genetic models, biomaterial applications, and translational approaches linking bench discoveries to clinical insights. Dr. Blum has been recognised through international collaborations, scientific contributions, and participation in excellence centres dedicated to neurodegenerative disease research. His honours reflect his influential role in advancing knowledge on Alzheimer’s disease, Huntington’s disease, and related disorders. Overall, he stands as a highly respected scientist whose integrative work continues to shape current understanding of neurodegenerative mechanisms and supports the development of innovative therapeutic strategies.

Profile: ORCID

Featured Publications

Mohamed Taha Moutaoufik | Neurodegenerative Diseases | Best Research Article Award

Published on by Cognitive Scientist Awards

Prof. Mohamed Taha Moutaoufik | Neurodegenerative Diseases | Best Research Article Award

Mohammed VI Polytechnic University | Morocco

Dr. Mohamed Taha Moutaoufik is an accomplished Moroccan molecular biologist and Assistant Professor at the University Mohammed VI Polytechnic, with a strong foundation in cell and molecular biology acquired through advanced studies at Université Laval and Université Ibn Zohr. His professional experience spans roles as a Research Associate and Postdoctoral Fellow at the University of Regina in Canada, where he contributed to cutting-edge research on protein interactions, mitochondrial biology, and neurodegenerative disease mechanisms. His scholarly involvement includes memberships in prestigious societies such as the Human Proteome Organization and the Mediterranean Neuroscience Society. Dr. Moutaoufik’s research interests center on proteomics, neurodegeneration, mitochondrial interactomes, and molecular mechanisms underlying Parkinson’s and Huntington’s diseases. He demonstrates expertise in multi-omics data integration, bioinformatics, protein-protein interaction mapping, and advanced molecular techniques. As an editor for Frontiers in Chemistry and related journals, he has overseen significant contributions to molecular biosciences. His numerous awards, including fellowships from the Canadian Institutes of Health Research and Parkinson Canada, reflect his research excellence and leadership in biomedical science. Overall, Dr. Moutaoufik exemplifies a dynamic researcher whose interdisciplinary work bridges molecular biology and neuroproteomics, advancing scientific understanding of cellular mechanisms and their implications for precision medicine.

Profile: ORCID

Featured Publications

Qura Ain | Phamagenetics | Women Researcher Award

Published on by Cognitive Scientist Awards

Dr. Qura Ain | Phamagenetics | Women Researcher Award

University College Dublin | Pakistan

Dr. Qura Tul Ain is a passionate pharmacogenetic researcher and medical doctor with a strong dedication to advancing knowledge in rare diseases, human genetics, and advanced health sciences. She completed her MBBS from the Services Institute of Medical Sciences in Lahore, where she gained extensive clinical exposure through rotations in medicine, surgery, intensive care, gynecology, and ophthalmology, and later pursued an MPhil in Pharmacology with a specialization in molecular genetics at Shifa Tameer-e-Millat University, Islamabad. Her academic training provided her with expertise in genomics, bioinformatics, and molecular pharmacology, with her thesis focusing on the pharmacogenetics of low-dose empagliflozin in patients with heart failure. Professionally, she has served as a demonstrator in pharmacology at Shifa College of Medicine, alongside clinical roles as a medical officer and house physician in both medicine and surgical departments. Her research interests include pharmacogenomics, molecular genetics, and personalized medicine, with a particular focus on identifying genetic markers that predict treatment outcomes in cardiovascular diseases. She is skilled in laboratory techniques such as PCR, RFLP, DNA/RNA extraction, and gel electrophoresis, which support her translational research. Her contributions have been recognized through research fellowships and academic opportunities, reflecting her commitment to bridging genetics and clinical therapeutics. With her strong foundation in medicine, research, and teaching, Dr. Qura Tul Ain is well positioned to make impactful contributions to precision medicine and healthcare innovation.

Profile: ORCID

Featured Publications

Jing Zhang | Medicinal Chemistry | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Jing Zhang | Medicinal Chemistry | Best Researcher Award

School of Life Sciences and Engineering | China

Dr. Jing Zhang, currently a lecturer at the School of Life Sciences and Engineering, Lanzhou University of Technology, is a dedicated scholar with a strong academic foundation built at Wuhan University, where she completed her bachelor’s and master’s studies in pharmaceutical sciences and medicinal chemistry and later earned a doctorate in pharmaceutical sciences. Her professional journey includes valuable research experience as a research intern at the Chinese Academy of Sciences in the Department of Magnetic Resonance Imaging, which enhanced her expertise in imaging technologies and drug delivery systems. Her research interests lie in the fields of nanomedicine, drug delivery, photodynamic and photothermal therapies, fluorine-based magnetic resonance imaging, and cancer therapeutics. She has contributed significantly to these domains through publications in high-impact journals such as Chemistry & Biodiversity, Advanced Healthcare Materials, The Journal of Organic Chemistry, and Chemical Communications, focusing on anticancer agents, traceable biomaterials, and estrogen receptor modulators. Dr. Zhang’s research skills span organic synthesis, polymer chemistry, molecular imaging, and the development of multifunctional nanocarriers for cancer treatment. Her achievements are further supported by prestigious research funding, including national and provincial projects and collaborations with pharmaceutical industries. Recognized for her diligence and truth-seeking approach, she continues to advance biomedical innovation with the potential to impact cancer diagnosis and therapy significantly, making her a promising leader in pharmaceutical sciences.

Profile: ORCID

Featured Publications

Milana Frenkel-Morgenstern | Liquid Biopsy | Women Researcher Award

Published on by Cognitive Scientist Awards

Dr. Milana Frenkel-Morgenstern | Liquid Biopsy | Women Researcher Award

Dr. Milana Frenkel-Morgenstern is an Israeli scientist and Principal Investigator at the Scojen Institute of Synthetic Biology, Reichman University. She specializes in bioinformatics, systems biology, and synthetic biology. With a rich background spanning molecular genetics, computer science, and structural biology, she has held key positions in institutions such as Bar-Ilan University, Weizmann Institute of Science, and the Spanish National Research Centre. She is renowned for her pioneering work in liquid biopsies, chimeric RNAs, and non-invasive diagnostic tools. Dr. Frenkel-Morgenstern has published extensively, served on prestigious evaluation panels, and received numerous fellowships and awards, including the Miguel Servet Fellowship and the Rector Prize for Scientific Innovation. Her leadership in both academic and public scientific communities, combined with a strong record of mentorship and university service, highlights her influential presence in biomedical research. She is also the founder of the “Art in Science” session at ISMB, reflecting her commitment to interdisciplinary innovation.

Profile

🎓 Education

Dr. Frenkel-Morgenstern earned her PhD in Molecular Genetics at the Weizmann Institute of Science under Prof. Shmuel Pietrokovski, specializing in bioinformatics and systems biology. Prior to that, she completed her MSc in Mathematics and Computer Science with a thesis in molecular biology from Bar-Ilan University, mentored by Prof. Ron Unger and Prof. Amihood Amir. Her undergraduate studies were also at Bar-Ilan University, where she earned a BSc in Mathematics and Computer Science. Her multidisciplinary education seamlessly blends life sciences, computational modeling, and mathematical analysis, forming the foundation for her later innovations in biomedical research. This strong computational background, coupled with a deep understanding of molecular biology, positioned her to excel in complex systems analysis, machine learning, and genomics, leading to a distinguished academic and research career. Her training has enabled her to lead translational biomedical projects, particularly in the fields of cancer research, structural bioinformatics, and synthetic biology.

🧪 Experience

Dr. Milana Frenkel-Morgenstern has over two decades of academic and research experience. She is currently Principal Investigator and Senior Lecturer at Reichman University. Prior to this, she was a senior faculty member at Bar-Ilan University’s Azrieli Faculty of Medicine for a decade. Internationally, she served as a staff scientist at the Spanish National Cancer Research Centre (CNIO) and was a postdoctoral fellow in the labs of Prof. Alfonso Valencia and Prof. Uri Alon. She has also been a scientific advisor and educator at the Weizmann Institute’s Davidson Institute. Dr. Frenkel-Morgenstern has taught a range of graduate-level courses in genomics, bioinformatics, and computational biology. She has been deeply involved in institutional governance, serving on data science boards, senate committees, and multiple departmental leadership roles. Her professional journey reflects a blend of research excellence, teaching dedication, and scientific outreach, including organizing the “Art in Science” initiative for ISMB/ECCB.

🏅 Awards and Honors

Dr. Frenkel-Morgenstern has received numerous prestigious awards recognizing her research and innovation. She was awarded the Rector Prize for Scientific Innovation by Bar-Ilan University in 2021, and the Bioinfo4Women Fellowship by the Barcelona Supercomputing Center from 2016–2019. Her work on RNA sequencing earned her the Miguel Servet Fellowship (2011–2015), and she received international postdoctoral fellowships from Caja Navarra Foundation and Horvitz Foundation. Her academic contributions have been recognized through several Travel Awards from ISMB, ECCB, and RECOMB, and she earned Outstanding Poster Awards in international conferences. As a guest editor for leading journals and evaluator for major funding bodies (ERC, ISF, GIF, etc.), her influence extends beyond research to shaping the global scientific agenda. She also received the Excellent Lecturer Award (2017) at Bar-Ilan University and serves as an academic reviewer and thesis evaluator for institutions across Israel, Europe, and Asia, demonstrating global academic leadership.

🔬 Research Focus

Dr. Frenkel-Morgenstern’s research centers on liquid biopsy technologies, cell-free nucleic acids (cfDNA/cfRNA), and systems and synthetic biology. Her lab investigates molecular biomarkers for cancer, arthritis, and prenatal diagnostics, developing computational platforms that utilize next-generation sequencing, AI, and machine learning. She explores chimeric RNAs, chromosomal translocations, and non-optimal codon usage, linking genetic regulation with disease mechanisms. Her interdisciplinary work bridges microbiome analysis, metagenomics, genome profiling, and protein-protein interaction networks, with translational applications in personalized medicine. In addition, she applies big data analytics to understand the cell cycle, identify druggable targets, and improve early diagnostics using non-invasive methods. Dr. Frenkel-Morgenstern is also investigating novel areas such as the relationship between melanin, Vitamin D, and mRNA technologies, relevant to both clinical and cosmetic science. Her research is both hypothesis-driven and data-intensive, aiming to convert large-scale biological data into practical medical insights and biotechnology solutions with significant societal impact.

✅ Conclusion

Dr. Milana Frenkel-Morgenstern is a leading scientist in bioinformatics and synthetic biology whose interdisciplinary research in liquid biopsies, systems biology, and AI-driven genomics continues to impact cancer diagnostics and translational medicine globally.

Publications

  • Applications for Circulating Cell-Free DNA in Oral Squamous Cell Carcinoma: A Non-Invasive Approach for Detecting Structural Variants, Fusions, and Oncoviruses

    Cancers
    2025-06 | Journal article | Author
    DOI: 10.3390/cancers17121901
    CONTRIBUTORS: Mahua Bhattacharya; Dan Yaniv; Dylan P. D’Souza; Eyal Yosefof; sharon tzelnick; Rajesh Detroja; Tal Wax; Adva Levy-Barda; Gideon Baum; Aviram Mizrachi et al.

  • ChiTaRS 8.0: the comprehensive database of chimeric transcripts and RNA-seq data with applications in liquid biopsy

    Nucleic Acids Research
    2025-01-06 | Journal article
    DOI: 10.1093/nar/gkae1126
    CONTRIBUTORS: Dylan DSouza; Lihi Bik; Olawumi Giwa; Shahaf Cohen; Hilit Levy Barazany; Tali Siegal; Milana Frenkel-Morgenstern

  • The applications of circulating cell-free DNA for oral squamous cell carcinoma patients as non-invasive diagnostics of structural variants, fusions and oncoviruses

    2023-11-30 | Preprint
    DOI: 10.1101/2023.11.29.23299177
    CONTRIBUTORS: Mahua Bhattacharya; Dan Yaniv; Eyal Yosefof; Sharon Tzelnick; Rajesh Detroja; Dylan P. D’Souza; Gidi Baum; Aviram Mizrachi; Gideon Bachar; Milana Frenkel Morgenster

Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Jim Jinn-Chyuan Sheu | Precision medicine | Best Researcher Award

Dr. Jim Jinn-Chyuan Sheu is a professor at the Institute of Biomedical Sciences, National Sun Yat-sen University, Taiwan, and an adjunct professor in several prestigious institutions. With a PhD in Life Science from National Tsing-Hua University, his academic and industrial experiences span cancer genetics, precision medicine, and biopharmaceuticals. He has held positions at Johns Hopkins Medical Institutions and Development Center for Biotechnology. His research explores molecular mechanisms underlying diseases such as cancer and endometriosis, employing genome-wide technologies to identify biomarkers and drug targets. He actively contributes to biomedical innovation, translational medicine, and mentorship. Dr. Sheu has received numerous national and international awards, including the Wu-Da-You Memorial Award and Sigma Xi membership. He is also an ambassador for the European Association for Cancer Research. As a prolific researcher and reviewer, he plays key roles in research councils and institutional review boards, helping shape scientific policy and translational biomedical advancements in Taiwan and beyond.

Profile

Education 🎓

Dr. Sheu earned his Ph.D. in Life Science from National Tsing-Hua University, Taiwan, in 2002, where he focused on advanced molecular biology, gene expression regulation, and biomedical research. His doctoral training provided a strong foundation in cancer genetics and systems biology. Earlier, he completed his B.S. in Biology (now Life Science) from Fu-Jen University in 1994, building core competencies in biological sciences and cellular mechanisms. These educational milestones equipped him with theoretical knowledge and technical skills in genomics, proteomics, and cellular signaling, which are now reflected in his research on chromatin remodeling, cancer biomarkers, and therapeutic targets. Through rigorous academic mentorship, Dr. Sheu gained early exposure to multidisciplinary research and critical analysis, fostering his interest in precision medicine. His academic background laid the groundwork for his contributions to biomedical research, drug development, and translational science. These formative years in Taiwan’s top universities underpin his long-standing excellence in scientific discovery and innovation.

Experience 👨‍🏫

Dr. Sheu’s professional experience includes faculty roles and research leadership across academia and industry. He has served as a Professor at National Sun Yat-sen University since 2014 and previously held faculty roles at China Medical University. Internationally, he was a Research Fellow at Johns Hopkins Medical Institutions (2004–2006). Between 2003–2004, he worked in various leadership positions at the Development Center for Biotechnology, including Director of Protein Drugs Division and Project Leader. His postdoctoral and early research roles included work with Dr. Tse-Wen Chang and Dr. Carmay Lim at Academia Sinica. His academic leadership includes roles such as Associate VP of R&D, Chair of the Institute of Biomedical Sciences, and Director of Research Resources at NSYSU. He has reviewed research proposals for numerous hospitals and institutions, served on IRBs, and guided government research policy. His diverse experience bridges basic science, translational research, and biomedical entrepreneurship with national and global impact.

Awards & Recognitions 🏅

Dr. Sheu has received over 30 prestigious awards. In 2023 alone, he earned the Tien-Te Lee Award, NSYSU Outstanding Faculty Award, and top honors at the 37th Joint Biomedical Conference. He previously received the Prof. Chii-Ruey Tzeng Award, Sigma Xi membership (2021), and EACR Ambassador role (2020). His innovation was recognized by Future Tech Award and the 2020 Smart Life Innovation Competition. His studies were featured as Taiwan Research Highlights and F1000Prime recommendations. He was the 2014 recipient of the Wu-Da-You Memorial Award and the IBC Outstanding Scientific Achievement Award. He received the Medical Young Investigator Award in 2009 and the Best Basic Science Award at Johns Hopkins in 2005. As a government-financed scholar to the U.S., his academic excellence has been internationally recognized. He consistently ranks among Taiwan’s top biomedical researchers, illustrating his impact through award-winning research in endometriosis, cancer stemness, diagnostics, and therapeutic innovation.

Research Interests 🔬

Dr. Sheu’s research focuses on cancer genetics and genomics, endometriosis, precision medicine, chromatin remodeling, cytoskeletal dynamics, cell adhesion and invasion, and mechanotransduction. His lab investigates how abnormalities in gene expression and chromatin structure drive disease progression, especially in gynecologic cancers and endometriosis. By applying genome-wide analysis and bioinformatics, his team identifies disease-driving genes and develops novel diagnostic tools and therapeutic strategies. A key interest is the tumor microenvironment and how cytoskeletal networks and nuclear architecture influence cancer stemness and metastasis. His group explores traditional Chinese medicine compounds and stem cell therapies, advancing integrative approaches to medicine. Antibody and vaccine engineering are also integral to his translational pipeline. Funded by NSTC Taiwan and other institutions, his projects target non-invasive diagnostics and biomarker-based interventions. His long-term vision involves bridging molecular biology, clinical application, and therapeutic innovation to impact patient care and global health through interdisciplinary and precision-driven biomedical science.

Publications

Fan Zhang | Proteomics | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Fan Zhang | Proteomics | Best Researcher Award

Fan Zhang, born on September 23, 1991, is a postdoctoral researcher specializing in cancer proteogenomics 🔬. He is currently with the Department of Pathology at Duke University 🏛️. His research leverages mass spectrometry and bioinformatics 🖥️ to investigate metabolic pathways in therapy-resistant prostate cancer and other malignancies. He has received the FY23 Prostate Cancer Research Program Early Investigator Research Award 🏆 for his work on glutamine metabolism in advanced prostate cancer. His contributions to proteogenomics have resulted in multiple high-impact publications 📄 in Nature Communications, Cell Research, and Molecular & Cellular Proteomics. Proficient in LC-MS/MS, bioinformatics analysis, and experimental techniques, his research bridges the gap between basic cancer biology and clinical applications 🏥, paving the way for novel therapeutic strategies in oncology.

Profile

Education 🎓

Fan Zhang holds a Ph.D. in Biochemistry and Molecular Biology from Fudan University (2015-2020), where he focused on proteogenomic research. He further pursued postdoctoral training in Clinical Medicine at Fudan University (2020-2022) before joining Duke University as a postdoctoral researcher in the Department of Pathology in 2023. His academic journey began with a B.S. in Applied Biological Science from Anhui Agricultural University (2011-2015). Throughout his education, he gained expertise in genomics, transcriptomics, and proteomics, developing a strong foundation in bioinformatics and experimental methodologies. His interdisciplinary training has equipped him with skills in mass spectrometry-based proteomics, omics data analysis, and cancer metabolism research. His current research at Duke University focuses on metabolic vulnerabilities in prostate cancer, aiming to develop targeted therapies. His diverse academic background enables him to integrate various scientific disciplines, contributing significantly to cancer research and precision medicine.

Experience 👨‍🏫

Fan Zhang has extensive research experience in cancer proteogenomics. Currently a postdoctoral researcher at Duke University (2023-present), he investigates metabolic vulnerabilities in prostate cancer using advanced mass spectrometry and omics analysis. Previously, he was a postdoc in Clinical Medicine at Fudan University (2020-2022), where he contributed to proteogenomic studies on various cancers, including pituitary neuroendocrine tumors and diffuse large B-cell lymphoma. His Ph.D. at Fudan University (2015-2020) focused on proteogenomic characterizations of cancer, leading to high-impact publications. He is proficient in LC-MS/MS, bioinformatics, and experimental methodologies such as Western blotting, immunofluorescence, and cell culture. His research integrates mass spectrometry with genomics and transcriptomics to uncover novel therapeutic targets. With expertise in multi-omics data analysis, he has significantly contributed to the field of cancer biology. His work is supported by prestigious grants, highlighting his role as a leading researcher in proteogenomics and precision oncology.

Research Interests 🔬

Fan Zhang’s research focuses on proteogenomics and cancer metabolism, particularly in therapy-resistant malignancies like prostate cancer, pituitary neuroendocrine tumors, and diffuse large B-cell lymphoma. He specializes in mass spectrometry-based proteomics (DDA, DIA) and integrates multi-omics approaches, including genomics, transcriptomics, and metabolomics, to uncover novel cancer vulnerabilities. His current work at Duke University investigates glutamine metabolism in castration-resistant prostate cancer, aiming to develop targeted therapies. His expertise extends to bioinformatics analysis, large-cohort omics data interpretation, and advanced LC-MS/MS techniques for various biological samples. His research has led to multiple high-impact publications, highlighting his ability to translate complex molecular data into potential clinical applications. By combining experimental and computational approaches, he aims to identify biomarkers and therapeutic targets that can improve cancer treatment. His contributions to proteogenomics play a crucial role in advancing precision oncology and understanding the metabolic reprogramming of aggressive cancers.

 

Awards & Recognitions 🏅

Fan Zhang has received multiple awards and recognitions for his contributions to cancer proteogenomics. He was awarded the Fiscal Year 2023 (FY23) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (2023-2025) for his project on targeting glutamine metabolism in advanced prostate cancer (Award Number HT9425-24-1-0237). His research has been recognized through multiple first-author and co-first-author publications in high-impact journals such as Nature Communications, Molecular & Cellular Proteomics, Cell Research, and The Prostate. His work has also been featured as a cover article in Cell Research (2022). His expertise in mass spectrometry, proteogenomics, and bioinformatics has positioned him as a leading young investigator in the field. In addition to research grants, he has received accolades for his innovative contributions to metabolic studies in oncology. His commitment to advancing cancer research has been instrumental in developing novel therapeutic strategies for therapy-resistant malignancies.

Publications 📚